https://doi.org/10.4081/cardio.2024.55
Pulmonary artery pressure sensor device performance in patients with atrial fibrillation/flutter
Published: December 30, 2024
Abstract Views: 66
Pdf: 0
APPENDIX: 12
APPENDIX: 12
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Previous studies have demonstrated that hemodynamic-guided management using implantable pulmonary artery (PA) pressure sensor device reduces heart failure (HF) hospitalizations in patients with HF. It is unclear if atrial fibrillation/flutter (AF) affect the performance of the PA pressure sensor.
Methods: Using the National Readmission Database (NRD) we examined 90-day HF-specific and all-cause readmission in patients with and without AF after PA pressure sensor implantation in the US from 2016 to 2020 in a propensity score matched analysis. Our cohort comprised of adult patients (≥18 years) with an ICD-10 procedural code for PA pressure sensor implantation.
Results: We included 1515 hospitalizations with PA sensor implantation for 90-day readmission analysis. Among patients implanted with the PA pressure sensor, 17.2% of patients without AF and 16.3% of patients with AF were readmitted primarily for HF within 90-days of discharge (Adjusted OR: 1.07, 95% CI 0.61 – 1.87, p = 0.800). Whereas, 36.3% of patients without AF and 33.9% of patients with AF were readmitted for any cause within 90-days of discharge (Adjusted OR: 0.85, 95% CI 0.53 – 1.37, p = 0.505). In subgroup analysis, there was no difference in HF-specific or all-cause readmission in AF patients with HF with reduced ejection fraction or HF with preserved ejection fraction when compared to those without AF.
Conclusions: Analysis of a large, real-world cohort of HF patients with implantable PA pressure sensor showed that HF-specific and all-cause readmissions at 90 days after PA pressure sensor implantation were comparable between patients with and without AF.
1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation 2020;141:e139-e596.
DOI: https://doi.org/10.1161/CIR.0000000000000746
2. Kwok CS, Abramov D, Parwani P, et al. Cost of inpatient heart failure care and 30-day readmissions in the United States. Int J Cardiol 2021;329:115-22.
DOI: https://doi.org/10.1016/j.ijcard.2020.12.020
3. Aliyev N, Almani MU, Qudrat-Ullah M, et al. Neighborhood Household income and trends in 30-day readmission for patients with heart failure. JACC Heart Fail 2023;11:121-3.
DOI: https://doi.org/10.1016/j.jchf.2022.10.003
4. Aliyev N, Almani MU, Qudrat-Ullah M, et al. Comparison of 30-day readmission rates and inpatient cardiac procedures for weekday versus weekend hospital admissions for heart failure. J Card Fail 2023;29:1358-66.
DOI: https://doi.org/10.1016/j.cardfail.2023.05.010
5. Siddiqi TJ, Arshad MS, Sreenivasan J, et al. Readmissions in patients with heart failure and mental health disorders (from a National Database). Am J Cardiol 2021;159:142-3.
DOI: https://doi.org/10.1016/j.amjcard.2021.08.002
6. Whellan DJ, Sarkar S, Koehler J, et al. Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. Am J Cardiol 2013;111:79-84.
DOI: https://doi.org/10.1016/j.amjcard.2012.08.050
7. Steinberg BA, Li Z, O’Brien EC, et al. Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. Hear Rhythm 2021;18:709-16.
DOI: https://doi.org/10.1016/j.hrthm.2021.01.021
8. Linssen GCM, Rienstra M, Jaarsma T, et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2011;13:1111-20.
DOI: https://doi.org/10.1093/eurjhf/hfr066
9. Eapen ZJ, Greiner MA, Fonarow GC, et al. Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J 2014;167:369-375.e2.
DOI: https://doi.org/10.1016/j.ahj.2013.12.001
10. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009;119:2516-25.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.821306
11. Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009;11):676-83.
DOI: https://doi.org/10.1093/eurjhf/hfp085
12. Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail 2020;22:1891-901.
DOI: https://doi.org/10.1002/ejhf.1943
13. Dickinson MG, Lam CS, Rienstra M, et al. Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure. Eur J Heart Fail 2017;19:1483-90.
DOI: https://doi.org/10.1002/ejhf.959
14. Wolfson AM, Yousefian O, Short L, et al. Effects of pressure variation and atrial fibrillation on CardioMEMS(TM) HF measured pulmonary artery diastolic pressure: comparison of device-averaged and visually inspected waveforms. Physiol Meas 2017;38:1094-103.
DOI: https://doi.org/10.1088/1361-6579/aa6edb
15. Lindenfeld J, Costanzo MR, Zile MR, et al. Implantable hemodynamic monitors improve survival in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2024;83:682-94.
DOI: https://doi.org/10.1016/j.jacc.2023.11.030
16. Katchi T, Orellana CP, Aggarwal C, Lanier GM. CardioMEMS sensor detects atrial arrhythmias before clinical decompensation. J Card Fail 2017;23:S92.
DOI: https://doi.org/10.1016/j.cardfail.2017.07.268
17. Krisai P, Johnson LSB, Moschovitis G, et al. Incidence and predictors of heart failure in patients with atrial fibrillation. CJC Open 2021;3:1482-9.
DOI: https://doi.org/10.1016/j.cjco.2021.07.016
18. Chamberlain AM, Redfield MM, Alonso A, et al. Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail 2011;4:740-6.
DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.111.962688
19. Hardman SM, Noble MI, Seed WA. Postextrasystolic potentiation and its contribution to the beat-to-beat variation of the pulse during atrial fibrillation. Circulation 1992;86:1223-32.
DOI: https://doi.org/10.1161/01.CIR.86.4.1223
20. Gosselink AT, Blanksma PK, Crijns HJ, et al. Left ventricular beat-to-beat performance in atrial fibrillation: contribution of Frank-Starling mechanism after short rather than long RR intervals. J Am Coll Cardiol 1995;26:1516-21.
DOI: https://doi.org/10.1016/0735-1097(95)00340-1
21. Zile MR, Bennett TD, El Hajj S, et al. Intracardiac pressures measured using an implantable hemodynamic monitor: relationship to mortality in patients with chronic heart failure. Circ Heart Fail 2017;10:e003594.
DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.116.003594
22. Kittipibul V, Fudim M, Silver MA, Yaranov DM. Discordant pressure-volume trends during CardioMEMS monitoring. JACC Heart Fail 2023;11:1150-1. d
DOI: https://doi.org/10.1016/j.jchf.2023.05.027
23. Costanzo MR, Stevenson LW, Adamson PB, et al. Interventions Linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail 2016;4:333-44.
DOI: https://doi.org/10.1016/j.jchf.2015.11.011
24. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-66. d
DOI: https://doi.org/10.1016/S0140-6736(11)60101-3
25. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet 2023;401:2113-23.
DOI: https://doi.org/10.1016/S0140-6736(23)00923-6
26. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991-1001.
DOI: https://doi.org/10.1016/S0140-6736(21)01754-2
27. Abraham WT, Adamson PB, Costanzo MR. et al. Hemodynamic monitoring in advanced heart failure: results from the LAPTOP-HF trial. J Card Failure 2016;22:940.
DOI: https://doi.org/10.1016/j.cardfail.2016.09.012
How to Cite
Almani, M. U., Alzubi, J., Yousuf, M., Alrawashdeh, R., Fatima, N., Al Madani, M., & Bonita, R. (2024). Pulmonary artery pressure sensor device performance in patients with atrial fibrillation/flutter. Global Cardiology, 2(4). https://doi.org/10.4081/cardio.2024.55
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Rafael Vidal-Pérez, Ewa A. Jankowska, The scientific targets: the myocardium, the vasculature and the body’s response to heart failure , Global Cardiology: Vol. 2 No. 1 (2024)
- Giuseppe M.C. Rosano, Jerneja Farkas, Evolving targets for heart failure: the journey so far , Global Cardiology: Vol. 1 No. 1 (2023)
- Giuseppe M.C. Rosano, Clinical trial design, endpoints and regulatory considerations in heart failure , Global Cardiology: Vol. 2 No. 1 (2024)
- Stephan von Haehling, Wolfram Doehner, Ruben Evertz, Tania Garfias-Veitl, Monika Diek, Mahir Karakas, Ralf Birkemeyer, Gerasimos Fillippatos, Piotr Ponikowski, Michael Böhm, Tim Friede, Stefan D. Anker, Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial , Global Cardiology: Vol. 1 No. 1 (2023)
- Camila Bedo, Juan C. Grignola, Preferential vasodilator effects of levosimendan in resistance pulmonary arteries in a rodent pulmonary embolism model , Global Cardiology: Vol. 2 No. 1 (2024)
- Jelena Čelutkienė, Agnė Monika Jakštaitė, Jolita Badarienė, Svetlana Solovjova, Ieva Slivovskaja, Rokas Navickas, Edita Kazėnaitė, Egidija Rinkūnienė, Alma Čypienė, Jonas Misiūra, Ligita Ryliškytė, Aleksandras Laucevičius, Andrew J.S. Coats, Detection of early heart failure with preserved ejection fraction in metabolic syndrome patients detected as part of a national screening program in middle aged subjects , Global Cardiology: Vol. 1 No. 1 (2023)
- Elena Efremova, Alexander Shutov, Adherence to lifestyle therapy in patients with chronic heart failure and comorbidity , Global Cardiology: Vol. 1 No. 1 (2023)
- Maryanne Caruana, Miriam Gatt, Oscar Aquilina, Charles Savona Ventura, Victor Grech, Jane Somerville, The impact of maternal congenital heart disease on pregnancy outcomes in Malta: a retrospective study , Global Cardiology: Vol. 1 No. 1 (2023)
- Khawaja M. Talha, Javed Butler, Stephan von Haehling, Mitja Lainscak, Piotr Ponikowski, Stefan D. Anker, Defining iron replete status in patients with heart failure treated with intravenous iron , Global Cardiology: Vol. 1 No. 1 (2023)
- Rachel Anne Xuereb, Sara Xuereb, Kentaro Yamagata, Robert George Xuereb, Anomalous origin of right coronary artery from the pulmonary artery: an incidental finding on cardiac computed tomography in a patient presenting with dyspnea , Global Cardiology: Vol. 2 No. 1 (2024)
You may also start an advanced similarity search for this article.
